Liminatus Pharma, Inc. (LIMN)
NASDAQ: LIMN · Real-Time Price · USD
1.240
+0.040 (3.33%)
Oct 24, 2025, 4:00 PM EDT - Market closed
Company Description
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies.
It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPα blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis.
The company was founded in 2018 is based in LA Palma, California.
Liminatus Pharma, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Chris Kim |
Contact Details
Address: 6 Centerpointe Drive, #625 La Palma, California 90623 United States | |
| Phone | 213 273 5453 |
| Website | liminatuspharma.com |
Stock Details
| Ticker Symbol | LIMN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001831874 |
| ISIN Number | US53271X1081 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Chris Kim J.D., L.L.M. | Chief Executive Officer and Chairman |
| Scott Dam | Chief Financial Officer |
| Dr. Beom Kyu Choi | Chief Technology Officer and Member of Scientific Advisory Board |
| Dr. Byong Chul Yoo Ph.D. | Chief Science Officer and Member of Scientific Advisory Board |
| Dr. Sang-jin Lee Ph.D. | Head of Research and Development and Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | 15-12G | Securities registration termination |
| Apr 16, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 10, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 25-NSE | Filing |
| Feb 7, 2025 | DEFM14A | Filing |
| Jan 28, 2025 | 425 | Filing |
| Jan 28, 2025 | 8-K | Current Report |
| Jan 16, 2025 | 425 | Filing |
| Jan 16, 2025 | 8-K | Current Report |